Of these, 47 (14.7%) reported a household member having symptoms suggestive of SARS-CoV-2 illness. Seroprevalence of Antibodies Against SARS-CoV-2 All participants tested at day time 1 (June 2020) Cerdulatinib were nasopharyngeal swab PCR negative for Mouse monoclonal to FOXD3 SARS-CoV-2 (Table 2 and Supplementary Table S3). had the highest seropositive prevalence pattern (21.3%, = 0.2). Thirty-eight per cent of seropositive HCPs reported earlier SARS-CoV-2 symptoms: 1.9 times higher odds than seronegative HCPs (= 0.01). Of 400 participants retested on day time 28, 13.3% were Luminex seropositive (92.5% previously, 7.5% newly). Thirty-two per cent of in the beginning seropositive HCPs were seronegative on day time 28. Conclusion With this large cohort of PCR-negative patient-facing oncology HCPs, almost one in five were SARS-CoV-2 antibody positive at the start of the pandemic’s first wave. Our findings that one in three seropositive HCPs retested 28 days later on became seronegative support Cerdulatinib regular SARS-CoV-2 PCR and antibody screening until common immunity is achieved by effective vaccination. Key phrases: Antibody, COVID-19, healthcare experts, PCR, SARS-CoV-2, serology Intro The global SARS-CoV-2 (COVID-19) pandemic offers caused considerable morbidity and economic turmoil across the world. Since the start of the pandemic, numerous populations in multiple Cerdulatinib countries have been tested for SARS-CoV-2 illness by polymerase chain reaction (PCR), with a wide range of reported asymptomatic positive carrier rates (4C80%) [[1], [2], [3], [4], [5]]. Antibody checks are the gold standard for providing evidence of exposure to pathogens following an adaptive immune response, including SARS-CoV-2 illness [6,7]. Rates of antibody seroconversion after SARS-CoV-2 illness seem to vary but have been consistently high. Good examples during the 1st wave of the pandemic include the 1st large Chinese series Cerdulatinib (= 285) of hospitalised SARS-CoV-2 PCR-positive individuals, where 100% developed SARS-CoV-2 IgG within 19 days of symptom onset [8]; a study of 624 SARS-CoV-2 PCR-positive outpatients, where 82% developed antibodies 10C14 days after sign onset [9]; and a study of 14 SARS-CoV-2 PCR-positive healthcare experts (HCPs), where 71% developed antibodies 15 days after PCR screening [10]. The significance of antibody generation in terms of subsequent disease safety is likely to be one of multiple mechanisms of SARS-CoV-2 immunity [11]. Most HCPs do not work directly with SARS-CoV-2-infected hospital inpatients. HCP seropositivity data collected during the 1st pandemic wave show a range of reported rates. A People from france HCP study reported three (1.3%) of 230 asymptomatic PCR-na?ve HCPs to be SARS-CoV-2 IgG positive. All three HCPs were PCR unfavorable at the time of testing, suggesting past exposure with successful eradication of the virus [10]. A Spanish HCP study reported an asymptomatic Cerdulatinib HCP SARS-CoV-2 seropositive rate of 7.6% (44/578) [12], and a Swedish study reported an overall HCP seroprevalence of 19.1% (410/2149), of which 1.2% (37/2149) were asymptomatic [13]. A UK study reported an asymptomatic IgG seroprevalence of 1% (4/400) and a symptomatic IgG seroprevalence of 3% (12/400) [14], whereas another UK study reported an asymptomatic IgG seroprevalence of 17.1% and a symptomatic IgG seroprevalence of 37.5% [15]. Data from screening asymptomatic HCPs for active SARS-CoV-2 viral contamination during the first pandemic wave show similar results. In the UK, one study showed a peak asymptomatic HCP contamination rate of 7.1% in late March 2020, decreasing to 1 1.1% 5 weeks later [16], whereas another study reported that 30 (3%) of 1032 asymptomatic hospital HCPs tested in April 2020 were SARS-CoV-2 PCR positive [17]. People with cancer may be more likely to contract SARS-CoV-2 contamination [18,19]. This risk is usually amplified by multiple hospital attendances required for diagnosis, treatment and follow-up. Although recent results suggest that systemic anti-cancer treatment (SACT) does not increase mortality in infected cancer patients [20], it may increase the risk of serious complications following contamination [18,19]. Although guidelines advise SARS-CoV-2 testing for cancer patients prior to and during SACT, the risks posed from and to HCPs working in oncology departments is not known. The COVID-19 Serology in Oncology Staff (CSOS) study is usually a multicentre UK study designed to determine SARS-CoV-2 contamination and antibody seroprevalence rates.